ALB and neoplasm: A new group of Alb-R26Met tumor-bearing mice was generated to constitute two cohorts treated with Decitabine or MEKi+BCL-XLi for ten days and compared with a non-treated cohort as control (Tables S7 and S8), then tumors were dissected and dissociated cells processed for spectral cytometry (Figure 7A).